Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) by Barosi, G et al.
haematologica 2004; 89(6):June 2004 717
GIOVANNI BAROSI
MARIO BOCCADORO
MICHELE CAVO
PAOLO CORRADINI
MONIA MARCHETTI
MASSIMO MASSAIA
GIAMPAOLO MERLINI
PATRIZIA TOSI
SANTE TURA
From the Laboratorio di
Epidemiologia Clinica, IRCCS
Policlinico S.Matteo, Pavia, Italy
(GB, MM); Divisione Universitaria
di Ematologia, Azienda
Ospedaliera San Giovanni
Battista, Turin, Italy (MB, MM);
Istituto di Ematologia ed
Oncologia Medica “Seragnoli”,
Università di Bologna, Bologna,
Italy (MC, PT, ST); U.O Ematolo-
gia, Trapianto di Midollo Osseo,
Istituto Nazionale dei Tumori,
Università degli Studi di Milano,
Milan, Italy (PC); Laboratorio di
Biotecnologie e Tecnologie
Biomediche, IRCCS Policlinico
S.Matteo, and Dipartimento di
Biochimica, Università di Pavia,
Pavia, Italy (GM); Laboratorio di
Ematologia Oncologica, Centro
Ricerche Medicina Sperimentale,
Turin, Italy (MM).
Management of multiple myeloma and
related-disorders: guidelines from the Italian
Society of Hematology (SIE), Italian Society of
Experimental Hematology (SIES) and Italian
Group for Bone Marrow Transplantation (GITMO) 
Correspondence:
Giovanni Barosi, MD, Laboratorio
di Epidemiologia Clinica, IRCCS
Policlinico S.Matteo, viale Golgi
19, 27100 Pavia, Italy.
E-mail: barosig@smatteo.pv.it
@2004, Ferrata Storti Foundation
Objectives. Perceiving the need for rigorous recommendations to facilitate decisions
concerning the management of patients with multiple myeloma (MM), the Italian Soci-
ety of Hematology (SIE) and the two affiliate societies (SIES and GITMO) commissioned
a project to develop guidelines for the therapy of MM using evidence-based knowledge
and consensus formation techniques.
Methods. After a comprehensive systematic review of 1,450 papers, an Expert Panel for-
mulated and graded sixty recommendations according to the supporting evidence. Evi-
dence gaps were filled with twenty-two consensus-based statements. High grade rec-
ommendations (grade A) are reported below.
Results. Treatment should be immediately initiated in MM patients with related organ
damage: those patients aged below 65 years who do not have severe co-morbidities
should receive autologous stem cell transplantation, while patients not candidates for
autologous stem cell transplantation should receive oral melphalan and prednisone. Inter-
feron-α should not be associated with conventional chemotherapy, but it can be offered
with or without steroids as a maintenance therapy to patients who have reached a plateau
phase. High-dose dexamethasone-containing regimens or high-dose dexamethasone
alone are recommended as a first-line therapy when cytoreduction is urgently required
(i.e., MM with spinal cord compression or with rapidly progressive renal failure). MM
patients with moderate-to-severe anemia should receive erythropoietin, while patients
with bone disease or osteopenia should receive long-term bisphophonates. Recommen-
dations for the management of the clinical manifestations caused by the monoclonal pro-
tein (i.e. hyperviscosity, cast nephropathy, AL amyloidosis) and of solitary bone and
extramedullary plasmacytoma were also elaborated. 
Conclusions. A substantial proportion of clinical care for MM can be guided by evidence-
based treatment recommendations.
Key words: multiple myeloma, clinical practice guidelines, systematic review, stem
cell transplantation, evidence-based knowledge.
A B S T R A C T
Multiple myeloma (MM) accounts for10% of all hematologic malignan-cies1 and is characterized by a poor
prognosis, the median overall survival (OS) of
patients receiving conventional chemothera-
py being only 36-40 months at the best insti-
tutions.2-3 Infections and renal failure are the
major life-threatening complications, while
anemia and bone disease are the principal
causes of the poor quality of life of MM
patients.4 Attempts to improve upon the dis-
mal clinical outlook of patients with MM and
to ameliorate their quality of life have been
made in recent years by investigating inno-
vative antitumor strategies and searching for
new interventions for bone, renal and infec-
tious complications.
Currently, physicians are facing the diffi-
cult task of innovating their therapeutic con-
duct according to the newly proposed strate-
gies. Subjective integration of older and new-
er pieces of evidence may lead to conflicting
conclusions and large variations in clinical
practice. Evidence-based treatment recom-
mendations may help physicians to offer
patients the best available treatments. Con-
sensus-based statements can be used when
evidence gaps occur in some relevant clinical
areas.
In 2001, the Italian Society of Hematology
(SIE) began an initiative to sponsor evidence-
and-consensus-based guidelines in the ther-
apy of selected diseases. In 2002 the Italian
Society of Experimental Hematology (SIES)
and the Italian Group for Bone Marrow Trans-
plantation (GITMO) shared this aim with SIE
and decided to focus their efforts on the ther-
apy of MM and related disorders. The guide-
lines elaborated during this project are pre-
sented here.
Multiple Myeloma • Decision Making and Problem Solving
[haematologica]
2004;89:717-741
 
Design and Methods
Organization
The SIE charged two chairmen (ST and GB) with the
development of the present guidelines: they invited an
Expert Panel (EP) of 7 senior hematologists, selected for
their expertise in research and clinical practice of MM.
An Advisory Council (GB and MM) was also convened
to support the systematic review of literature and the
consensus phase.
Literature inquiry
The Advisory Council searched the following evidence
bases: PubMed, CancerLit, the Cochrane Library, and
EMBASE. The first search was performed on 20th July
2002, however, relevant papers published up to 31st May
2003 were subsequently searched. The basic search
strategy adopted was: “Myeloma/therapy*” in MESH.
The major hematology, oncology and general medicine
journals (Blood, Journal of Clinical Oncology, British
Journal of Haematology, Bone Marrow Transplantation,
Haematologica, New England Journal of Medicine) were
manually searched for relevant papers published from
1992 to 2002. Additionally, the proceedings of the lat-
est annual meetings were searched for relevant unpub-
lished evidence: American Society of Hematology
(1995-2002), Italian Society of Hematology (2002),
European Haematology Association (2002). The full ref-
erence list of the comprehensive systematic review of
1,450 papers (including the abstracts of full papers) is
available on request from marchettim@smatteo.pv.it.
Definitions
During the first consensus conference, the EP agreed
on the following definitions to be used in the present
guidelines:5,6
Asymptomatic myeloma: bone marrow B-cell-derived
clonal disease that is diagnosed through the demon-
stration of a monoclonal component (MC) in serum ≥ 30
g/L and/or bone marrow plasma cells ≥ 10%; no symp-
toms or disease-related organ damage or tissue impair-
ment .
Symptomatic multiple myeloma: bone marrow B-cell-
derived clonal disease that is diagnosed through the
demonstration of MC in serum and/or urine; bone mar-
row plasma cells ≥ 10%; disease-related organ damage
or tissue impairment, including bone lesions.
Non-secretory myeloma: bone marrow B-cell-derived
clonal disease that is diagnosed through the demon-
stration of bone marrow plasma cells ≥ 10%, disease-
related organ damage or tissue impairment, including
bone lesions; no MC in serum and/or urine or assessed
by immunofixation.6
Disease-related organ damage: bone lesions (lytic
lesions or osteoporosis with compression fractures), ane-
mia (hemoglobin 2 g/dL below the lower limit of normal
or hemoglobin <10 g/dL), renal insufficiency (creatinine
>173 mM/L), symptomatic hyperviscosity, recurrent bac-
terial infections (> 2 episodes in 12 months), amyloido-
sis, hypercalcemia (serum calcium >0.25 mM/L above
the upper limit of normal, or > 2.75 mM/L).6
Solitary plasmacytoma of bone: B-cell-derived malig-
nancy that is diagnosed through the demonstration of
a single area of bone destruction due to clonal plasma
cells; bone marrow not consistent with MM; normal
skeletal survey (and magnetic resonance imaging [MRI]
of spine and pelvis if done); no MC in serum and/or urine
(a small MC may sometimes be present); no disease-
related organ or tissue impairment.6
Extramedullary plasmacytoma: B-cell-derived malig-
nancy that is diagnosed through the demonstration of
extramedullary tumor of clonal plasma cells; normal
bone marrow; normal skeletal survey;no MC in serum
and/or urine (a small MC may sometimes be present); no
disease-related organ or tissue impairment.6
Disease plateau: stable MC values (within 25% above
or below the value at the time response was assessed)
maintained for at least 3 months.5
Refractory disease: minimal decrease or increase
(<25%) in the concentration of serum or urinary MC
and/or an increase in the size of existing bone lesions
and/or development of new bone lesions, soft tissue
plasmacytomas or hypercalcemia not attributable to any
other cause.
Relapse from complete remission: reappearance of
serum or urinary MC on immunofixation or routine elec-
trophoresis, confirmed by at least one further investiga-
tion and excluding oligoclonal immune reconstitution
and/or >5% plasma cells in a bone marrow aspirate or
on trephine bone biopsy; development of new lytic bone
lesions or soft tissue plasmacytomas or definite increase
in the size of residual bone lesions (development of a
compression fracture does not exclude continued
response and may not indicate progression) and/or
development of hypercalcemia (corrected serum calci-
um > 11.5 mg/dL or 2.75 mM/L) not attribuable to any
other cause.5
Evidence analysis
During the first consensus conference, the EP also
agreed on the major areas of concern in the therapy of
MM, thus identifying the therapeutic issues for the
guidelines. Each member of the EP, along with a mem-
ber of the AC, was assigned to one or more therapeutic
issues. The member of the AC reviewed and selected the
available evidence and graded its quality. The grading
system chosen for the present project is the one elabo-
rated by the Scottish Intercollegiate Guideline Network.7
This system primarily classifies evidence according to
the study design, thus assigns randomized trials to lev-
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el 1, cohort and case-control studies to level 2, and case
reports to level 3. Studies belonging to levels 1 and 2 can
be further classified into three levels, namely ++, + and
-, according to the study and reporting quality. We
assigned phase II studies to evidence level 2. Relevant
studies (i.e. reports of randomized clinical trials) report-
ed in abstract form only could not be assigned a quali-
ty level, but were uniquely classified according to their
study design. In the comment to each recommendation,
the authors stated whether abstract-based evidence
played a relevant role in supporting a specific statement.
Evidence deriving from studies not enrolling patients
with MM was defined translated, according to the SIGN
system and assigned a one-step lower evidence level
than it would have been given according to the study
design and quality if it had dealt with MM patients.
Formulation of recommendations
Each member of the EP formulated evidence-based
recommendations based on the literature review: he/she
also added expertise-based recommendations when rel-
evant areas could not be addressed by the available evi-
dence but indirect evidence could support a statement.
Recommendations for therapeutic choices were either
positive (suggestion to perform an action), negative
(suggestion not to perform an action), indifferent (option
to choose among two or more non-superior therapies)
or provisional (positive indication to enroll patients into
clinical trials testing the index therapy). All the recom-
mendations were graded class A if supported by consis-
tent and applicable level 1 evidence (at least one level
1++ trial or some consistent level 1+ trials), class B if
evidence was derived from consistent results of level
2++ studies or was extrapolated from level 1+/1++ tri-
als, class C if supported by grade 2+ studies that could
be applied directly to the object population and provid-
ed consistent results, or level 1++ studies from differ-
ent populations (translated evidence), and grade D when
supported by  poor quality evidence or evidence extrap-
olated from grade 2+ studies, and thus sustained main-
ly by the experts’ opinion.
A first round of consensus for the proposed recom-
mendations was obtained through paper questionnaires,
according to the Delphi Panel technique. The AC meshed
the Panel comments and the full body of recommenda-
tions was finally discussed during four Consensus Con-
ferences held in Milan on 4 July 2002, 20 October 2002,
19 December 2002 and 25 January 2003.
Results
Frontline therapy: indications to start
treatment
Patients with symptomatic MM should be treated
immediately. In contrast, for patients with asymptomatic
MM, immediate chemotherapy does not offer any sur-
vival benefit over that provided by delayed chemother-
apy, as convincingly demonstrated by several controlled
studies8,9 and confirmed by a recent meta-analysis pool-
ing the results of these trials.10 Thus, patients with MM
but no related organ damage must be followed up close-
ly and should start treatment when signs of disease pro-
gression develop. The time to disease progression for
these patients is reported to vary from less than 1 year
to approximately 3 years, and may be predicted by sev-
eral factors.11-13 Skeletal-related events (i.e. pathologic
fractures, hypercalcemia) were reported to occur in a
certain fraction of patients at the time of progression
into symptomatic MM.13 MRI of the spine may help in
assessing impending bone complications.14
Ongoing studies are evaluating bisphosphonates
and/or thalidomide as initial therapy for patients with
asymptomatic MM. However, only preliminary data on
the efficacy of these drugs on progression into sympto-
matic disease are available.15 Therefore, evidence in this
setting was judged by the Expert Panel not sufficient to
recommend the routine use of these drugs in clinical
practice, outside approved clinical trials.
Recommendations
Treatment must be started immediately in patients
with MM and related organ damage (anemia, hypercal-
cemia, bone lesions, renal failure, hyperviscosity, amyloi-
dosis, recurrent bacterial infections) (grade A).
Organ damage should be assessed through the follow-
ing evaluations: full blood count, serum calcium, serum
creatinine, urinary protein, total body X-ray survey, MRI
of the spine, periumbilical fat fine-needle biopsy (aimed
to assess amyloid fibrils in patients with clinical or labo-
ratory features that suggest the presence of amyloidosis),
fundus oculi (aimed to assess the presence of hypervis-
cosity-related lesions in patients with MC > 40 g/L)
(grade D).
Patients with untreated MM should be carefully mon-
itored by physical examination, full blood count, meas-
urement of both serum and urinary MC, serum calcium,
serum creatinine, skeletal X-ray (of the spine, pelvis,
femur, humerus), and MRI of the spine in patients with
MC>30 g/L or IgA MC or Bence Jones (BJ) proteins > 50
mg/day (grade D)
Monitoring of all the above cited aspects, except skele-
tal imaging, should be repeated at 3 monthly intervals in
the first year of follow-up and every 6 months afterwards,
if the disease remains in a steady state. Skeletal evalua-
tions can be performed only once a year (grade D).
Autologous stem cell transplantation
Studies on autologous stem cell transplantation (SCT)
as a means to overcome chemoresistance in MM
patients in whom conventional therapy failed were pio-
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neered in the mid 1980s.16-18 Once the feasibility and
efficacy of this procedure had been demonstrated in
advanced and refractory disease, autologous SCT was
subsequently performed also as primary therapy for
patients with newly diagnosed disease. Over the last
decade, the interest in this treatment modality has pro-
gressively grown and many thousands of patients have
so far received autografts worldwide. Autologous SCT
for MM currently accounts for more than 25% of all
autografts performed in Europe (with the European
Bone Marrow Transplant registry having accrued 8362
patients reported from 1986 to 2000)19,20 and is the sec-
ond most frequent indication for autologous SCT in the
United States.21 Two prospective, randomized trials22,23
and one population-based study24 comparing conven-
tional chemotherapy with a single autologous SCT as
first-line treatment for patients aged less than 60-65
years demonstrated the significant benefit from autol-
ogous SCT in terms of an increased complete remission
(CR) rate, up to 20-40%, and extended event-free sur-
vival (EFS) and OS (by 12 to 15 months). However, no
plateau in EFS curves could be discerned, suggesting
that a single autologous SCT was not curative.
Based on these findings, attempts were made by sev-
eral groups to improve the results by administering two
sequential courses of high-dose therapy and double (or
tandem) autologous SCT. Results of a phase II pilot study
showed that repeated administrations of melphalan at
200 mg/m2 could be given safely, with a cumulative
mortality rate below 3%, and significantly prolonged
the survival in a pair-mate comparison with conven-
tional chemotherapy.25 Following this study,5 prospec-
tive, randomized trials were started in Europe aimed at
exploring the value of double autologous SCT in com-
parison with a single transplantation as primary thera-
py for MM patients under the age of 60-65 years.
Results of these studies were recently updated26-30 and
are summarized in Table 1. Briefly, two studies showed
a significant improvement and prolongation in EFS
(from 10% to 20% at 7 years and from a median value
of 25 months to 34 months, respectively) with double
autologous SCT,26,29 a finding confirmed also by a trial of
double intensive, non-myeloablative therapy and sub-
sequent autologous SCT.28 Importantly, the 7-year pro-
jected OS for patients assigned to double autologous
SCT was double that observed in the single transplant
arm (42% versus 21%, respectively).26 In contrast, two
other studies failed to demonstrate any difference in
EFS and OS between single and double autologous
SCT.27,30 The divergence of survival curves after 4 to 5
years from the start of treatment observed in the French
study should raise some caution against any premature
conclusion concerning the role of double autologous
SCT in studies without a sufficiently long follow-up
period.
Transplant-related mortality (TRM) in younger
patients with normal renal function who receive high-
dose therapy with PBSC support is generally below 5%.
However, the risk  increases up to 10% or more if the
transplant is performed in older patients or in patients
with renal failure. The impact of age on outcome of SCT
was analyzed in two studies.31,32 In one study, no statis-
tically significant difference was found in terms of OS
and EFS between patients older than 65 years and
younger pair-mates treated with full dose melphalan
(200 mg/m2) and double autologous SCT.31 In the other
study, the rate of mortality related to double autologous
SCT in patients older than 70 years was 16%, a value
lowered to 2% following a reduction in the dose of mel-
phalan to 140 mg/m2.32
In a pair-mate comparison of intensified therapy with
PBSC support versus conventional chemotherapy for
patients over 60 years of age, the intensified therapy
was reported to be of benefit in terms of increased CR
rate and extended OS.32 Taken together, these studies
showed that older patients, at least up to 70 years of
age, can be considered for autologous SCT (provided
their performance status and organ function are satis-
factory) and may eventually benefit from this procedure.
However, the degree of benefit from autologous SCT in
comparison with that from conventional treatment can-
not be quantified until prospective randomized trials
specifically address this issue. The mortality rate in
patients with MM and impaired renal function treated
with full dose melphalan (200 mg/m2) and single or dou-
ble autologous SCT was reported to be 7% and 13%,
respectively.33,34 No significant improvement in EFS and
OS was demonstrated for patients who received double
autologous SCT in comparison with patients who were
treated with a single course of high-dose therapy.
Decreasing the dose of melphalan from 200 mg/m2 to
140 mg/m2 was associated with reduced mucositis and
lower TRM, and, more importantly, did not adversely
affect the outcome of SCT.33 A retrospective comparison
between patients with renal failure and pair-matched
controls with normal renal function failed to demon-
strate any difference between the two groups in terms
of 3-year projected OS.35 Thus, it can be concluded that
the presence of renal failure should no longer be con-
sidered a contraindication to autologous SCT in MM.36,37
The optimal dose of melphalan for these patients is 140
mg/m2,
The issue of the best source of hematopoietic stem
cells (i.e. bone marrow versus peripheral blood stem
cells) was addressed in a prospective randomized study.38
A trend towards improved survival with PBSC trans-
plantation was observed, suggesting that peripheral
blood may be the recommended source of stem cells
also in MM patients. In order to collect a sufficient num-
ber of stem cells (i.e. CD 34+ cells), chemotherapeutic
haematologica 2004; 89(6):June 2004720
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agents that are toxic to bone marrow stem cells (pri-
marily, melphalan and nitrosoureas) and large volume
radiation therapy to marrow-containing bones should be
strictly avoided. Older age does not impair stem cell har-
vesting and cannot be considered an exclusion criteri-
on.39
Available data to support the choice of the best mobi-
lization therapy are limited; only 3 randomized clinical
trials have addressed this issue and 2 of them had a lim-
ited sample size.40-42 Results showed the superiority of
combined stem cell factor, filgrastim and cyclophos-
phamide over cyclophosphamide plus filgrastim,40 as well
as of combined cyclophosphamide and filgrastim over
either filgrastim alone41 or cyclophosphamide alone.42
Cyclophosphamide, at the dose of 3-4 g/m2, and G-CSF
is one of the most commonly used regimens in clinical
practice. The issue of the best conditioning regimen to be
administered before autologous SCT was addressed in a
randomized, multicenter clinical trial comparing mel-
phalan at a dose of 200 mg/m2 with combined total body
irradiation (TBI) (8 Gy) plus melphalan at a dose of 140
mg/m2.43 Melphalan at 200 mg/m2 was associated with a
significantly better 4-year probability of OS, as well as
with decreased toxicity and a shorter duration of hospi-
talization. Full dose melphalan is thus considered the
gold standard treatment to be used before autologous
SCT for MM.
The feasibility and efficacy of purging methods aimed
at providing a tumor-free source of repopulating
hematopoietic stem cells were investigated in several
phase II studies and one large, randomized multicenter
clinical trial.44 Although a marked reduction, by approx-
imately 3 logs, in the number of myeloma cells con-
taminating the graft was frequently reported,45 purged
autologous SCT did not improve the OS over that pro-
duced by unpurged SCT.45,46 Purging methods are expen-
Table 1. Comparative studies of autologous SCT in multiple myeloma.
Reference Study Country Rando- N. of Age Regimens Median CR EFS OS 
mized patients (years) follow-up (%) (median, (median,  
(months) months) months)
Standard chemotherapy versus single autologous SCT
Attal22 IFM France Yes 100 58 VMCP/BVAP×18 versus 108 14 18 44
100 57 VMCP/BVAP×4-6→Ctx 38 28 57
+ MEL 140 + TBI 8Gy (p<0.001) (p<0.01) (p<0.03)
Child23 MRC VII UK Yes 200 56 ABCM×4-12 versus 42 8 20 42
201 55 CVAMP×3→Ctx + MEL 200 44 32 54 
(p<0.001) (p<0.001) (p<0.04)
Blade21 PETHEMA Spain Yes* 83 56 ABCM/VBAD×12 66 11 34 67
81 56 ABCM/VBAD×4→MEL 200 30 43 65 
(p<0.002)
Single versus tandem autologous SCT
Attal26 IFM94 France Yes 199 52 VAD×3-4→G-CSF→MEL140 75 42 25 48
200 52 + TBI 8Gy versus MEL140; 50 30 58
MEL140 + TBI 8Gy (p<0.1) (p<0.03) (p<0.01)
Cavo29 BOLOGNA Italy Yes 110 53 VAD×4→CTX→MEL 200 38 21 25 56
96 110 53 versus MEL 200; 24 34 60
MEL 120 + Busulfan (p<0.05)
Fermand27 MAG France Yes 97 50 DEX×2→CTX→VAD×3-4 53 39 31 49
95 96 50 →MEL140+ VP16 + CTX 37 33 73
+ TBI 12Gy versus MEL 140; (p=0.14)
Mel 140 + VP16 + TBI 12Gy
Sonneveld28 HOVON Germany Yes° 129 55 VAD×3-4X→CTX→MEL70×2 40 14 4yr:15% 4yr:15% 
132 56 VAD×3-4X→CTX→MEL70×2 28 versus 29% versus 33% 
→CTX + TBI 8Gy (p<0.004) (p<0.03) (p<0.3)
Standard chemotherapy versus tandem autologous SCT
Barlogie25 SWOG, US No 152 52 VMCB(P)/VBAP(P)/VAD 114 NA 16 43
TTI 152 52 VAD×2-3→CTX→EDAP 41 37 79
→MEL200×2 (p<0.0001) (p<0.0001)
(<PR, MEL140+TBI 8.5Gy)
*Responders to induction; °after VAD.
 
sive and may delay immunological reconstitution,
thereby increasing the risk of infections following autol-
ogous SCT.47,48
Attempts to prolong the duration of disease control,
and possibly the OS, following autologous SCT were
made by using IFN-α as maintenance treatment and
by giving consolidation chemotherapy before mainte-
nance treatment. A single study that prospectively com-
pared IFN-α versus no therapy reported a significant
benefit from the IFN-α in terms of prolonged progres-
sion-free survival (PFS) and OS at a median follow-up
of 52 months; however, the gain was lost after 77
months.49 Two additional non-randomized studies, pos-
sibly influenced by selection bias, further supported the
beneficial role of IFN-α in extending the duration of
OS and PFS after autologous SCT.50,51 Data concerning
the role of post-SCT consolidation chemotherapy are
currently too limited52 to draw definitive conclusions.
Multivariate analyses aimed at identifing the risk fac-
tors affecting transplant outcome showed the strong
and independent prognostic relevance of several vari-
ables, including β-2 microglobulin, C-reactive protein,
lactic dehydrogenase and creatinine levels.21,23,25,53,54
Chemosensitive disease before autologous SCT was also
associated with a good prognosis.53 However, refrac-
toriness to conventional therapy does not preclude a
favorable outcome with autologous SCT,55 particularly if
high-dose therapy is administered within 1 year of diag-
nosis.56 Cytogenetic abnormalities, as identified by con-
ventional karyotype and/or FISH analysis, provide addi-
tional important prognostic information. In particular,
chromosome 13 monosomy and/or deletions portend a
poor prognosis and identify a subset of patients who
will not benefit from double autologous SCT,53,54,57,58
whereas the t(11;14) correlates with a favorable out-
come of SCT.59,60 Finally, there is a consensus concerning
the value of post-transplant attainment of CR as a sur-
rogate marker of extended OS and EFS,21,61 independ-
ently of the treatment program (namely, either single or
double autologous SCT) by which this important goal is
achieved.
Recommendations
Patients with MM who are younger than 65 years
should receive high-dose chemotherapy and a single
autologous stem cell transplant (SCT), provided that they
are free of severe co-morbid conditions (grade A). Dou-
ble autologous SCT should be performed in those
patients who fail to achieve complete remission (CR)
after the first SCT (grade B).
Older age (more than 65 years) and renal failure are
not per se exclusion criteria for SCT (grade B). Thus,
patients aged 65-70 years can undergo SCT, provided
that they are free of severe co-morbid conditions and
are enrolled into approved clinical trials (grade B).
Peripheral blood is the preferred source of autologous
stem cells for the transplant (grade B).
The minimum number of CD34+ cells that needs to be
harvested in order to assure prompt hematopoietic
recovery following high-dose therapy is 2×106 /Kg per
each planned transplantation (grade B). The use of mel-
phalan before stem cell collection should be avoided
(grade B) and radiotherapy must be limited to highly
selected patients (grade B).
There is not enough evidence to recommend one mobi-
lization regimen with respect to another: the most com-
monly employed regimen includes cyclophosphamide
and G-CSF (grade B).
Purging of harvested cells is not recommended
because it has no beneficial impact on the duration of
survival (both OS and EFS) and can be detrimental since
it may be associated with an increased risk of infections
(grade A).
High-dose melphalan (200 mg/m2) is the gold stan-
dard treatment for patients below 65 years and/or with
normal renal function (grade A). Dose-reduction (140-
100 mg/m2) should be considered in order to decrease
the toxicity in patients older than 65 years and in
patients with renal impairment.
There is insufficient evidence to recommend consoli-
dation chemotherapy after autologous SCT (grade B).
IFN-α (alone or associated with steroids) is not rec-
ommended as routine maintenance therapy after autol-
ogous SCT, but it can be considered within approved clin-
ical trials (grade B).
Data are insufficient to recommend the use of steroids
or thalidomide as maintenance therapy after autologous
SCT, thus these therapies should be used only within
approved clinical trials.
Allogeneic SCT
More than 2000 MM patients have received allo-
geneic SCT worldwide and the annual rate in Europe is
about 300 procedures/year.19 Although the mortality
related to transplantation has recently significantly
decreased in comparison with the past TRM,62 fatal
complications – most frequently, infections – still occur
in 25% to 30% of patients, a value much higher than
that expected with autologous SCT. It should be noted
that TRM is twice as high in patients with graft-versus-
host disease (GVHD),63 while the lowest TRM (8%) is
encountered for syngeneic grafts.64 A low TRM is also
reported in upfront transplants.65 Contrariwise, TRM is
high in patients over 50 years of age,66 in recipients of
grafts from unrelated donors,67 and in those with
advanced refractory or progressive disease.65
In comparison with autologous SCT, patients surviv-
ing allogeneic SCT attain more frequent and more
durable molecular remissions, as a result of the well
recognized graft-versus-myeloma effect.63,68-83 Overall
haematologica 2004; 89(6):June 2004722
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survival at 3 years after an allogeneic SCT is 56%, and
declines quite slowly thereafter.62 Unfortunately, no
plateau has been observed in the survival curves.62
Different conditioning regimens can be employed for
allogeneic SCT: TBI-based conditioning regimens and
busulfan-cyclophosphamide regimens produced simi-
lar TRM, CR and CR durations.84-88 The outcomes of non-
myeloablative allogeneic SCT have been assessed in 22
case series enrolling overall 270 patients, mainly with
refractory/relapsed disease.89-91 A lower TRM was report-
ed with the non-myeloablative regimens compared with
myeloablative conditioning regimens, but the long-term
benefit is currently unknown.90 Non-myeloablative allo-
geneic SCT has also been employed as consolidation
after autologous SCT, along with donor lymphocyte
infusion (DLI),92,93 but this is still an experimental inter-
vention.
Recommendations
Current data do not support the standard use of allo-
geneic SCT from matched related donors as primary
therapy for MM (grade B). Myeloablative allogeneic SCT
from a sibling donor may be considered frontline treat-
ment for patients aged <50 years who are not expected
to benefit from autologous SCT, for example are patients
with chromosome 13 deletion. However this procedure
should be performed in the context of approved clinical
trials.
If a twin donor is available, syngeneic SCT should be
offered frontline up to 65 years of age (grade B). Unre-
lated donor SCT is not currently recommended and must
therefore be performed only in the context of approved
clinical trials (grade D).
Allogeneic SCT should favor the use of peripheral stem
cells (grade B from translated level 1+ evidence). Evi-
dence does not support a clear-cut advantage of TBI-
based preparative regimens, thus the choice depends
upon the center’s policy, the availability of TBI and the
patient’s prior exposure to radiation (grade B). The use of
reduced-intensity or non-myeloablative conditioning
regimens is still experimental and should be performed
in the context of approved clinical trials. There is no evi-
dence to recommend alternative regimens to
cyclosporine and methotrexate for GVHD prophylaxis
since this combination remains the standard immuno-
suppressive regimen in myeloablative allogeneic SCT
(grade B). Maintenance therapy is not recommended in
recipients of an allogeneic SCT.
Standard chemotherapy
The first evidence that chemotherapy improved the
prognosis of MM patients in comparison with placebo
dates back to the late 1960s.94 Melphalan, first intro-
duced in 1958, and subsequently supplemented with
prednisone (MP),95 has been the highway of conven-
tional therapy for several decades, although the
response rate is only in the 50-60% range and the
median OS does not exceed 3 years.96,97 Melphalan is
easy to use on an out-patient basis and has a low pro-
file toxicity; however, it should be used with caution in
patients with renal failure,98 and should be avoided in
patients who are candidates for a subsequent autolo-
gous SCT.99,100
Combined chemotherapy regimens, including or not
melphalan, have been widely explored in an attempt to
improve the prognosis of MM patients. Two recent
meta-analyses considering 3,814 and 6,633 patients
demonstrated that combined chemotherapy failed to
significantly extend the OS in comparison with that
achieved by MP, at the expense of increased toxicity
and worse tolerance.96,97 Regimens including melphalan
and/or nitrosourea are toxic to hematopoietic stem cells
and should be avoided if stem cell harvesting is planned.
Vincristine and doxorubicin, given by 4-day continuous
infusion, along with pulsed dexamethasone (VAD) was
initially used as salvage therapy for patients in whom
prior alkylating agent therapy failed,101 and subsequently
as primary induction of remission for previously
untreated patients.102,103 In comparison with MP, the VAD
regimen has several advantages, including that it pro-
duces a more rapid response, dose reductions are not
needed in the case of impaired renal function and, more
importantly, it does not cause stem cell injury.104,105 Due
to these properties, VAD has become the most popular
treatment used in clinical practice in an attempt to
reduce tumor cell mass before autologous SCT. Howev-
er, in more recent years the popularity of VAD has been
tempered by its major disadvantages, which include the
inconvenience and economic costs of a 4-day continu-
ous infusion, the risk of cathether-related infections
and thrombosis, as well as its toxicity (alopecia, cardiac
toxicity, neurotoxicity). Some of the major toxicities of
VAD may be overcome, or at least reduced, by admin-
istering pulses of high-dose dexamethasone. Although
no controlled clinical trial has so far been conducted in
an attempt to evaluate the role of this regimen in com-
parison with VAD as primary induction of remission,
both the rate and rapidity of response reported in a
phase II study with dexamethasone alone106 make this a
suitable therapy also for patients with newly diagnosed
MM, particularly those with severe pancytopenia and/or
impaired renal function.
After the role of thalidomide in the management of
patients with advanced and refractory MM had been
established,107 many phase II and phase III studies were
designed in an attempt to evaluate the efficacy and
toxicity of combined thalidomide-dexamethasone as
first-line therapy for patients with newly diagnosed dis-
ease. Preliminary results of 3 phase II studies so far
reported were promising and suggested that this regi-
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men may provide a valid alternative to VAD or high-
dose dexamethasone for induction of remission in
younger MM patients who are candidates to receive
autologous SCT.108-110 However, evidence is not sufficient
to recommend the use of thalidomide and dexametha-
sone in routine clinical practice, outside the context of
approved clinical trials. IFN-α was added to cytotoxic
drugs as front-line induction of remission in an attempt
to improve the results obtained with chemotherapy
alone. Two meta-analyses of both individual patient
data and published data showed marginal, albeit sig-
nificant, benefits from combined chemotherapy and
IFN-α in comparison with chemotherapy alone. The
benefits were seen in increased response rate and
extended PFS (by 5-6 months), but not in OS.111,112 More-
over, in the IFN-treated patients the quality of life was
significantly reduced during the first year of therapy.113
The role of IFN-α as maintenance therapy following
remission induction chemotherapy114 was also investi-
gated. A small, but significant, prolongation of PFS, by
4-7 months, and OS, by approximately 7 months, was
reported for IFN-α in two meta-analyses of published
studies.111,112 A third meta-analysis evaluated the long-
term survival of patients treated with IFN-α; no signif-
icant benefit in mean lifetime survival was demonstrat-
ed in these patients.115
Therapeutic advantages offered by IFN-α must be bal-
anced against the toxicity and side-effects reported by
most of the patients. Side effects may be mild in a cer-
tain fraction of patients, and eventually resolve after the
first weeks of treatment. However, in approximately 20-
30% of cases treatment discontinuation is required due
to relevant side effects.111,112 Toxicity may reduce the qual-
ity-adjusted survival advantage to clinically non-rele-
vant values.113 Finally, it can be predicted that approxi-
mately 50% of patients will refuse IFN-α therapy if side
effects and potential clinical benefits of IFN-α are clear-
ly illustrated in advance.116
In a randomized clinical trial addition of alternate-day
prednisone to IFN-α was reported to be more effective
than IFN-α alone.117 In contrast, there is no proof that
monthly courses of high-dose dexamethasone are supe-
rior to daily doses of prednisone, whereas alternate-day
prednisone at the dose of 50 mg significantly increased
the PFS and OS in comparison with alternate-day pred-
nisone at the dose of 10 mg.118
Recommendations
Melphalan and prednisone is the treatment of choice
for previously untreated patients with symptomatic MM
who are not candidates for autologous SCT (grade A).
The most commonly employed regimen is the following:
oral melphalan at 0.25 mg/kg/day×4 days and prednisone
2 mg/kg every day for 4 days. The therapy should be
repeated every 28 days until a plateau is reached.
Combination chemotherapy offers no clear advantage
over melphalan and prednisone in terms of extended sur-
vival (grade A).
Dexamethasone-containing regimes (VAD or VAD
hybrids) should be preferred for patients who require rap-
id cytoreduction (i.e. patients with renal failure, hyper-
calcemia, spinal cord compression, hyperviscosity syn-
drome) (grade C).
High-dose dexamethasone should be given as initial
therapy in patients with renal failure, pending decisions
on subsequent chemotherapy and the outcome of full
supportive measures, and/or in patients with severe pan-
cytopenia. Subsequent combination chemotherapy in
patients with renal failure should be VAD-based (grade C).
In patients with renal failure who are not candidates for
autologous SCT and for whom adriamycin or dexam-
ethasone are contraindicated, melphalan or cyclophos-
phamide-based regimens should be dose-reduced; oral
melphalan should not be used in patients with a glomeru-
lar filtration rate (GFR) below 30 mL/min, unless they are
on hemodialysis. The initial melphalan dose should be
reduced to 50% if the GFR is below 40 mL/min (grade D).
The cyclophosphamide dose should be reduced by 25% if
the GFR is below 40 mL/min and by 50% is the GFR is less
than 10 mL/min (grade D). 
Thalidomide, in combination with dexamethasone or
chemotherapy, cannot be recommended as routine first-
line therapy and should be used in the context of an
approved clinical trial (grade D).
IFN-α should not be associated with first-line conven-
tional chemotherapy given the lack of clinical benefit
(grade A). Patients who respond to first-line convention-
al chemotherapy can be offered IFN-α as maintenance
therapy with or without steroids (grade A). Despite the
high-level evidence supporting the efficacy of IFN-α, the
strength of this recommendation is low because of the
modest clinical benefit, weighed against the frequent side
effects. Standard treatment with IFN-α is 3 MU sc three
times a week. No recommendation can be made regard-
ing the duration of treatment. Data are insufficient to
recommend the use of pegylated-IFN instead of standard
IFN-α.
Data are insufficient to recommend the use of steroids
alone or thalidomide as maintenance therapy after stan-
dard chemotherapy, thus these therapies should be used
only within approved clinical trials.
Therapy for refractory and relapsed patients
Salvage therapy is offered to a heterogeneous group
of patients, including those who are primary refractory
to, or progress on first-line therapy, and patients relaps-
ing (either with a resistant or a sensitive disease) after
frontline therapy. The clinical difference among these
subgroups has been reported.119,120 Candidates for autol-
ogous SCT who are primary refractory to VAD-based
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therapy may benefit from subsequent high-dose
chemotherapy and autologous SCT.3,21,55, 84,121 Patients who
are not candidates for autologous SCT and who are pri-
mary refractory to frontline conventional chemothera-
py, may primarily benefit from thalidomide and/or fur-
ther standard chemotherapy.15,107,122-141
Relapse or disease progression eventually occurs in
most patients who receive autologous SCT, whether sin-
gle or double, or allogeneic SCT. Provided that sufficient
autologous stem cells are available, patients relapsing
after a single transplantation may undergo a second
autograft, however TRM increases up to 10%.77,84,142-146 In
contrast, a rescue transplant for patients relapsing after
prior frontline double autologous SCT was reported to
be associated with an OS of 19% at 2 years.63 In patients
progressing or relapsing after allogeneic SCT, donor lym-
phocyte infusions (DLI) can induce a complete
response.73,147
Patients relapsing after several lines of treatments
have been treated with novel drugs, such as thalido-
mide, alone or associated with dexamethasone, or pro-
teasome inhibitors.148,149
Response rates to thalidomide increase as the cumu-
lative dose of this drug increases,133,150 but good response
rates may also be achieved with doses of 200 mg per
day or lower,151-153 and tolerability is better with a low-
dose schedule. Unfortunately, patients with cytogenet-
ic abnormalities have a worse prognosis also with
thalidomide treatment.133 Dexamethasone and eventu-
ally added chemotherapy further increase response
rates to thalidomide, but also significantly increase the
thromboembolic risk, which may reach up to 5% per
treatment month.154-156 Nevertheless, venous throm-
boembolism did not prove to have a negative impact on
patients’ survival,155 and most patients could continue
thalidomide and dexamethasone therapy without pro-
gression or relapse of venous thromboembolism.157
Thalidomide frequently induces sensory-motor neuro-
logic defects which may be irreversible.158,159
Recommendations
Management of refractory patients
Patients who are not candidates for autologous SCT
and are primary refractory to MP should receive thalido-
mide associated or not with conventional chemothera-
py (grade B).
Candidates for autologous SCT who proved primary
refractory to VAD are recommended to proceed to autol-
ogous SCT (grade A).
Patients who proved refractory to autologous SCT,
should not be enrolled into a further autologous SCT and
should receive thalidomide associated or not with con-
ventional chemotherapy.
A thalidomide dose of 200 mg/day is effective and
well-tolerated (grade B). Combinations of thalidomide
with either high-dose dexamethasone or chemotherapy
should be preferred. Patients who are treated with
thalidomide combined with dexamethasone, and possi-
bly additional chemotherapy, should be monitored for
thromboembolic complications and should receive pro-
phylaxis against deep vein thrombosis (grade C). How-
ever, evidence is not sufficient to provide recommenda-
tions regarding the best prophylaxis of thromboem-
bolism in these patients.
Management of relapsed patients
Patients not eligible for first-line autologous SCT and
who have relapsed after first-line MP should receive
thalidomide with or without conventional chemothera-
py (grade B).
Patients who relapse after autologous SCT should be
offered an allogeneic SCT, provided that they are younger
than 50 years and have a family donor: the procedure
should, however, be performed within approved clinical
trials. When relapse occurs after a prolonged remission
or there is not a matched sibling donor and autologous
stem cells are available (> 2×109/Kg), a further autolo-
gous SCT is recommended, below the age of 65 years
(grade B): over the age of 65, the same procedure may be
considered with a dose reduction. Debulking is recom-
mended before both autologous and allogeneic SCT
(grade D).
The recommended treatment for patients who relapse
after autologous SCT, when neither a matched donor nor
autologous stem cells are available, is thalidomide asso-
ciated with dexamethasone, and possibly added
chemotherapy (grade B). DLI should be considered for
patients who progress or relapse after allogeneic SCT
(grade B).
Myeloma complications
Renal failure
Approximately 20% of patients with multiple myelo-
ma have a creatinine level ≥ 2.0 mg/dL (173 µmol/L) at
diagnosis. The two major causes of compromised renal
function are urinary light chain excretion and hyper-
calcemia. Dehydration, infection, non-steroidal anti-
inflammatory agents, and roentgenographic contrast
media may contribute to acute renal failure.160,161 The risk
of renal failure with roentgenographic contrast media
is minimal if dehydration is avoided. In fact, less than
1% of all episodes of acute renal failure in MM patients
were temporally related to administration of contrast
media.162 Hyperuricemia may contribute to renal insuf-
ficiency but can be treated easily. Amyloid deposition
may also contribute to renal failure.
Renal function may recover in more than half of the
patients,161,163-165 usually within the first three months.163,166
Recovery of renal function has been shown to improve
OS in most studies.165-172
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Maintenance of a high urine output (3 L/day) is
important in order to prevent renal failure in patients
with Bence Jones proteinuria. Prompt treatment of
hypercalcemia and correction of dehydration and elec-
trolyte imbalance are also crucial. Acute renal failure
may be reversed by a high fluid intake (> 3 L/24h).165
Patients randomized in a controlled trial to take alkali
fared marginally better than the others, but the differ-
ence was not statistically significant.165 Plasma
exchange is effective in removing the monoclonal light
chains  responsible  for renal failure,173-176 and may
restore normal renal function in more than half of
patients.177-179 The efficacy of plasma exchange in pre-
venting the initiation or continuation of dialysis is more
evident in patients with rapidly progressive renal fail-
ure secondary to MM.167,175 A small randomized trial167
and a non-randomized comparative study179 also report-
ed an improvement in OS in patients treated with plas-
ma exchange: the OS benefit was mainly prolonged in
those patients whose renal function recovered.
Recommendations
Renal failure should be prevented in MM patients by
avoiding dehydration (grade D) and nephrotoxic drugs
(non-steroidal anti-inflammatory agents, nephrotoxic
antibiotics), by promptly treating infections and by cor-
recting dehydration, hypercalcemia and hyperuricemia
(grade D). 
Renal biopsy is not essential in MM patients who have
renal failure. Furthermore, the risk of severe peri-proce-
dural bleeding in patients with amyloidosis should be
carefully evaluated.
MM patients with renal failure should be rehydrated
with intravenous fluids (saline) to achieve a urine flow of
over 3 liters per day (grade B). Evidence is not sufficient
to recommend urine alkalinization. 
Plasma exchange in combination with corticosteroids
is recommended in MM patients with rapidly progress-
ing renal failure (grade B). 
Dialysis should be offered to patients with end-stage
renal disease. Both hemodialysis and peritoneal dialysis
are equally effective long-term replacement therapies
(grade B). Evidence is not sufficient to recommend renal
transplantation in MM patients with end-stage renal
failure.
Anemia
Anemia is present in two thirds of patients at diag-
nosis of MM. Anemia reflects the course of the disease
since it worsens during resistant or progressive disease,
but it ameliorates when the disease is controlled by
treatment. Recombinant human erythropoetin (rHuEpo)
has extensively been used throughout the course of the
disease to increase Hb concentration, to reduce trans-
fusion requirement, and to improve the quality of life
(QoL). A total number of 630 MM patients were ran-
domized in 8 trials examining anemia and erythropoi-
etin use.180-187 Eligibility criteria most often included
hemoglobin values below 10 g/dL.180-187 The response rate
varied from 31% to 78% depending on the criteria for
defining response. These values are similar to those
observed in the general cancer population.188 In MM,
the response rate was influenced by the disease dura-
tion,187 the ratio between the observed and the predict-
ed serum erythropoetin concentration,183 and the rHuE-
po dose.183,184 The response rate at 4 weeks was the most
powerful predictor of a durable response.186 Two ran-
domized studies183,184 reached the conclusion that 5000
UI per day is the optimal dose (e.g, from 30,000 to
40,000 UI per week). This cumulative dosage can safe-
ly be given once weekly.189 Both direct181 and translated
evidence from a miscellanous cancer population indi-
cates that rHuEPO has a definite effect on the QoL
which is directly related to the improvement of ane-
mia.185,188,190-192 So far, no statistically significant benefit on
OS has been reported.186
Darbepoetin-α has recently been assessed in a dou-
ble-blind randomized trial that enrolled 344 MM and
lymphoma patients193 and found to be effective on
hematologic parameters and QoL.
Recommendations
MM patients with a hemoglobin level below 10 g/dL
should receive rHuEPO (grade A).
The initial dose should not be lower than 30,000
UI/week (grade B).
rHuEPO should not be continued in MM patients who
have not experienced an increase of hemoglobin con-
centration of at least 1 g/dL after 4 weeks of treatment
(grade D).
Full blood count, reticulocyte count, and iron status
(serum ferritin, serum transferrin saturation) should be
assessed before starting therapy and monitored during
the treatment (grade D).
Bone lesions
Several randomized trials have shown that, compared
to placebo, bisphosphonates reduce skeletal-related
events (SRE) and bone pain in MM patients. One meta-
analysis by the Cochrane Myeloma Group pooled data
from 11 randomized trials comparing oral clodronate,
intravenous pamidronate or intravenous ibandronate
versus placebo.194 This meta-analysis, including a total
of 2,183 assessable patients, showed a pooled reduction
of 41% in vertebral fractures and a significant reduc-
tion of pain in patients treated with biphosphonates
rather than placebo. Subgroup analysis showed that
bisphosphonates significantly reduced the occurrence of
SRE in early stage MM patients who received
pamidronate (level 2)195 or clodronate (level 1+)196,197 in
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the absence of bone lesions. Another subgroup analy-
sis showed that pamidronate  reduced SRE in MM
patients who already had skeletal fractures before study
entry.198 Notably, MM patients with advanced disease
(on a second or subsequent antimyeloma regimen) who
received pamidronate lived longer than MM patients
who received placebo.198 A few randomized studies have
been published subsequently to the meta-analysis by
Cochrane Myeloma Group.
One study compared intravenous ibandronate versus
placebo, but did not show any positive effect on bone
morbidity or OS.199 Two randomized studies were
designed as non-inferiority studies and compared intra-
venous zoledronic acid with intravenous pamidro-
nate.200,201 These studies also introduced time to first SRE
as an additional statistical end-point to minimize the
bias of analyses based only on events per person-
years.202 Pamidronate and zoledronic acid showed sim-
ilar effects on bone mobidity and similar safety profiles.
These conclusions have very recently been confirmed in
the 25-month final analysis of one of the studies.200
The optimal duration of bisphosphonate therapy is
not known since most of the trials report follow-ups
shorter than 24 months with the exception of the above
mentioned recent study203 in which intravenous
pamidronate or zoledronic acid were safely adminis-
tered every 3-4 weeks for 24 months. However, renal
failure and hypocalcemia may occur at any time during
therapy with bisphosphonates. Thus, careful monitoring
is mandatory, with special attention being given to
serum levels of creatinine and calcium, and albuminuria.
Any unexplained albuminuria (more than 500 mg/24
hours) or any increase of more than 0.5 mg/dL in serum
creatinine or an absolute value of more than 1.4 mg/dL
in MM with normal baseline values requires discontin-
uation of the drugs until the renal problem is resolved.
Bisphosphonates are also employed to treat hyper-
calcemia in association with hyperhydration.
Pamidronate has been shown to be superior to placebo
and clodronate,204,205 while ibandronate has been shown
to be superior to placebo.206 More recently, zoledronic
acid has been proven more effective than pamidronate207
as it produces a higher complete response rate, a longer
response duration, and a longer time to relapse.
Recommendations
MM patients with bone disease or severe osteopenia
(either newly diagnosed or relapsed or refractory) should
receive bisphosphonates (grade A). Long-term therapy
(at least 12 months) is recommended (grade D).
According to the preferences of both the physician and
the patient, the following treatments may be offered:
oral clodronate at 1600 mg/day, intravenous
pamidronate 90 mg every 4 weeks,  intravenous zole-
dronate 4 mg every 4 weeks (grade D).
Serum creatinine, urea and total calcium and urinary
albumin should be monitored before and during treat-
ment (grade D). Dose reduction should be considered for
patients with renal failure who require bisphosphonates
for bone disease (grade D).
Any unexplained albuminuria (more than 500 mg/24
hours) or any increase greater than 0.5 mg/dL (44
µmol/L) in serum creatinine or an absolute value of more
than 1.4 mg/dL (124 µmol/L) in a MM patient with nor-
mal baseline values requires discontinuation of bispho-
sphonates (grade D).
Treatment of MM-related hypercalcemia should be
started at a corrected serum calcium level greater than
3.00 mMol/L (or 12 mg/dL) (grade A).
Patients should be hydrated with saline to maintain
diuresis greater than 2.5 L/day and should receive intra-
venous bisphosphonates (grade B): a single dose of 4 mg
zoledronic acid should be infused in 15 minutes and with
an infusion volume of 100 mL, in order to limit the fre-
quency of renal complications (grade B). Retreatment
with the same drug (zoledronic acid), at higher doses (8
mg), may be considered for patients who relapse or who
are refractory to prior therapy (grade B).
Spinal cord compression
The frequency of spinal cord compression at presen-
tation is based on old studies that reported values in
the range of 6-24%.208,209 Malignant extradural spinal
cord compression (SCC) may cause pain (local or radic-
ular), weakness, sensory disturbance and/or sphincter
dysfunction. The loss of neurologic function may be irre-
versible and patients with paralysis either at presenta-
tion or post-treatment have a shorter life expectancy.210,211
In general, there were very few papers of high method-
ologic quality dealing with the emergency treatment of
malignant SCC. Two randomized trials in mixed patient
populations which included MM showed that dexam-
ethasone is effective on neurologic symptoms and
pain.212,213 An evidence-based guideline for the emergency
treatment of malignant SCC confirmed the efficacy of
high-dose dexamethasone.210 Radiotherapy is also effec-
tive in controlling back pain.214,215
Radiotherapy is less useful if a vertebral collapse is
the cause of the spinal cord compression. Surgical
decompression, such as posterior laminectomy, can be
effective in MM patients with neurologic symptoms of
spinal cord compression,216 especially if caused by a ver-
tebral collapse. A clinical improvement was also noted
in 82% of the patients refractory to the previous radio-
therapy,217 however, laminectomy has a mortality rate of
6-10% and did not prove superior to radiotherapy.218,219 In
general, recovery of neurologic functions after treat-
ment is mainly dependent on pretreatment levels: only
30% of non-ambulatory patients and 2-6% of para-
plegic ones regained the ability to walk.215,22 Thus,
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patients should be aggressively screened and educated
about SCC.210
Kyphoplasty is a new vertebroplasty technique in
which cement is percutaneously introduced to produce
vertebral augmentation: it involves the insertion of a
balloon-like inflatable bone tamp into the vertebral
body and the creation of a cavity, followed by insertion
of a thick viscous cement into the preformed cavity. In
a prospective study of 18 MM patients, kyphoplasty
restored 34% of the height loss without relevant com-
plications221 and with a significant improvement in the
patients’ functional status.222
Recommendations
MM patients with spinal cord compression should
immediately receive high-dose dexamethasone therapy
(grade A). If spinal cord compression is due to bone frag-
ments (and not to myeloma protruding masses) patients
should also undergo surgery (grade B). Those patients
who have neurologic impairment (deficits and/or symp-
toms) should also receive local radiotherapy (grade C).
Candidates for surgery should receive radiotherapy post-
operatively, once healing has occurred (grade C). Patients
should be aggressively screened and educated about
spinal cord compression (grade C). Patients with impend-
ing bone fractures of the hip or long bones should receive
surgery (grade C).
Hyperviscosity syndrome
Less than 2% of the MM patients present with hyper-
viscosity at diagnosis and a few more develop it after-
wards.223,224 Clinical manifestations of hyperviscosity
include mucosal hemorrhage, visual abnormalities along
with neurologic and cardiac features such heart failure,
seizures, vertigo, and diploplia. Serum viscosity levels do
not correlate well with the patients’ symptoms or clin-
ical signs. Venous dilatation and retinal hemorrhage are
evident at fundus oculi examination. These findings are
more important than the viscosity level in evaluating
the patient. It should be noted that hyperviscosity may
not be correlated with the amount of circulating M pro-
tein, but usually the MC concentration is > 40 g/L.225 The
treatment of hyperviscosity is aimed at preventing com-
plications such as bleeding, loss of vision and irre-
versible neurologic impairment. Automated plasma
exchange requires replacement of about two-thirds of
the patient's plasma volume with 5% human albumin
solution or an equal mixture of albumin and 0.9% nor-
mal saline.226,227 The procedure induces a dramatic
response soon after the first plasma exchange session.228
Therapeutic apheresis procedures are relatively safe,
with a 3% to 4% overall incidence of adverse effects
that are mostly reversible.229,230 It is important to repeat
the procedure at scheduled intervals, generally on a dai-
ly basis for 3 to 5 days until the hyperviscosity has been
corrected and chemotherapy is initiated. In the absence
of other treatments, cessation of plasma exchange
treatments will result in a recurrence of symptoms
within 2-3 weeks.231 The evidence on the efficacy of
plasma exchange in MM is limited to case series,232-234
but the American Society of Apheresis has provided
consensus-based recommendations for its use to treat
symptomatic hyperviscosity in MM patients.227
Recommendations
MM patients with symptomatic hyperviscosity should
be treated with plasma exchange until definite therapy
can be initiated (grade C). Plasma exchange (3-4 liters)
replaced with albumin 5% should be repeated at sched-
uled intervals until symptoms disappear (grade C).
Chemotherapy should be started promptly once hyper-
viscosity has been stabilized by plasma exchange.
Infections
Infections are a primary cause of death in MM
patients: the risk increases during induction chemother-
apy, after autologous and allogeneic SCT, and during
long-term maintenance with steroids. A randomized,
controlled trial showed that intravenous immunoglob-
ulin prophylaxis protected against life-threatening
infections and reduced the risk of recurrent infections.235
The Panel deemed that CDC and IDSA guidelines on
prophylactic vaccinations and the use of antimicrobial
agents in neutropenic cancer patients were applicable
to MM patients.236,237 Use of antibiotic prophylaxis is not
routine except for the use of trimethoprim-sul-
famethoxazole to prevent Pneumocystis carinii pneu-
monitis because of emerging antibiotic resistance.
Admission for intravenous antibiotic therapy is usually
needed for severe systemic infection. Despite the lim-
ited immunogenicity of vaccines against Streptococcus
pneumoniae and Haemophilus influenzae type B (HiB)
in autologous and allogeneic transplant recipients,
these vaccines are recommended because the majority
of such patients have low levels of antibodies to cap-
sular polysaccharides after transplantation. In particu-
lar, allogeneic recipients with chronic GVHD are at an
increased risk of infection from encapsulated organ-
isms (i.e., Haemophilus influenzae type B, Streptococ-
cus pneumoniae, Neisseria meningitidis). Seasonal
influenza vaccination is safe for MM patients, 20% of
whom develop protective immunity.238 It can be esti-
mated from translated evidence that influenza vacci-
nation has the potential to reduce the rates of severe
respiratory illness and related mortality by 50% in
patients achieving protective immunity.237,239 An Italian
trial randomized 50 MM patients to receive or not
influenza vaccination. Upper respiratory illness occurred
in 32% versus 72% of the vaccinated or not vaccinat-
ed patients, respectively; moreover, the mean durations
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of febrile respiratory episodes and hospitalizations, and
the number of non-programmed medical consultations
were lower in the vaccinated patients.240
Recommendations
Routine use of intravenous immunoglobulins (IVIG) is
not recommended as a general prophylaxis for bacterial
infection in MM patients: this therapy is reserved to
patients with recurrent infections and polyclonal
hypogammaglobulinemia or to recipients of allogeneic
grafts who experience severe hypogammaglobulinemia
within the first 100 days after the transplant (grade C).
The initial IVIG dose should be 0.4 g/Kg every 3-4 weeks
to reach serum IgG levels greater than 500 mg/dL. The
dose should then be individualized to maintain serum IgG
concentrations greater than 500 mg/dL (grade B).
Data are insufficient to recommend the use of prophy-
lactic antibiotics during conventional chemotherapy-
induced neutropenia. However, trimethoprim-sul-
famethoxazole is recommended to prevent Pneumocys-
tiis carinii pneumonia in patients receiving high-dose
dexamethasone. Prophylactic antibiotics or antiviral
agents should be provided to SCT recipients, according
to generally accepted guidelines (CDC). 
Evidence is insufficient to recommend the use of Strep-
tococcus pneumoniae and Haemophilus influenzae type
B (Hib) vaccines in all the MM patients receiving con-
ventional chemotherapy (grade B).
HiB vaccination should be offered to autologous and
allogeneic SCT recipients at 12, 14 and 24 months after
transplantation, independently of the recipients’ age
(grade B). The currently available 23-valent pneumococ-
cal polysaccharide vaccine is recommended at 12 and 24
months after SCT: the second dose provides a further
chance to patients who failed to respond to the first one
(grade B). 
Seasonal influenza vaccination is recommended to all
MM patients. SCT recipients should continue seasonal
vaccination lifelong, beginning before the transplant and
resuming 6 months after it. Family members and close or
household contacts of allogeneic SCT recipients should
also receive seasonal influenza vaccination before trans-
plantation and for 2 years thereafter (grade B).
Amyloidosis
Light chain amyloidosis (AL) occurs in approximately
12 to 15% of patients with MM. Patients with MM and
AL amyloidosis are definitely more fragile than patients
with only MM because of the several and/or severe
organ dysfunctions. Controlled studies suggest that
treatment with melphalan and prednisone may provide
a marginal survival benefit.241 Autologous SCT may offer
potential for long-term benefit,242 and although patients
are highly selected, response rates can approach
60%.243,244 The TRM of autologous SCT is over 20% even
in centers with particular experience of the procedure,
thus accurate selection of patients is necessary to limit
the TRM.242 Stem cells should be collected even in
patients temporarily not candidates for SCT, but with a
forseeable improvement in organ function. In those
patients with a potentially reversible contraindication to
ASCT, high-dose dexamethasone245 should be employed
in order to preserve the bone marrow stem cells. After
harvesting or in patients definitely not candidates for
autologous SCT, high response rates can be achieved
with the association of melphalan 0.22 mg/Kg plus high-
dose dexamethasone 40 mg given orally on days 1-4
every 28 days.246 Patients who are not eligible for high-
dose dexamethasone (i.e. those with refractory ventric-
ular arrhythmias, gastro-intestinal bleeding, or psy-
chosis) should be treated with standard MP. Refractory
or relapsing patients can be treated with intermediate
dose dexamethasone (20 mg orally on days 1-4, every 21
days) and thalidomide (starting from 100 mg/day and up
to 200 mg/day). Thalidomide has been shown to be
effective in AL patients, but poorly tolerated.247-249 Dan-
gerous bradycardia may occur during thalidomide ther-
apy, and therefore dynamic ECG monitoring (Holter) is
recommended monthly during thalidomide treatment.
Recommendations
AL amyloidosis in MM patients below 60 years old
should be treated with high-dose chemotherapy followed
by SCT provided that the patient has no more than 2
organs involved and does not have severe heart involve-
ment (grade B).
In patients aged between 60 and 65 years old and with
a serum creatinine equal to or greater than 2 mg/dL (173
mmol/L), the procedure should be considered with cau-
tion and the melphalan dose should be reduced to 100
mg/m2 (grade D).
Stem cell harvesting at diagnosis should be considered
also in those patients who are initially ineligible for
autologous SCT, but who do not have severe heart failure
(i.e. their NYHA class is I or II), symptomatic hypotension
or recurrent syncope, since these patients can tolerate
the cell harvesting procedure and may subsequently
become eligible for autologous SCT. These  patients
should avoid melphalan before stem cell harvesting. After
harvesting, patients  can be treated with oral melphalan
(0.25 mg/Kg) plus oral high-dose dexamethasone (40 mg)
for 4 days, every 28 days (grade C). Patients who are not
eligible for high-dose dexamethasone should be treated
with standard MP.
Refractory or relapsing patients can be treated with
intermediate dose dexamethasone (20 mg orally, 4 days
every 21 days) and thalidomide (from 100 mg/day up to
200 mg/day) (grade D). Monthly Holter monitoring is rec-
ommended during thalidomide therapy in order to detect
dangerous bradycardias promptly (grade D).
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Plasmacytoma
Solitary bone plasmacytoma (SBP) and extramedullary
plasmacytoma (SEP) are rare plasma cell proliferative
disorders. The diagnosis of plasmacytoma is based on
histologic confirmation of monoclonal plasma cell infil-
tration of a single disease site and on the exclusion of
systemic MM. SBP accounts for about 5% of all plas-
ma cell disorders.1 It is often localized in the spine (25-
60% of the cases) and over 40% of the patients have
spinal cord compression.250-252 Local radiotherapy
achieves remission in over 86% of the cases in a medi-
an time of 5 months,253,254 normalizes the MC levels in
20-50% of patients,253,255 and allows recovery from neu-
rologic impairment and symptom relief.253,256 The effica-
cy of radiotherapy has only been assessed in non-com-
parative retrospective studies: local recurrence occurs in
3-26% of the patients within the first 5 years after radi-
ation,257,258 whereas no recurrence was reported in small
series of patients treated with more than 35-40 Gy.259,260
Doses above 50-70 Gy are potentially toxic to the spinal
cord and are usually avoided. The median OS time of
patients treated with radiotherapy is 10 years.256
Transformation to MM occurs in 20% of the cases
within one year from diagnosis and in 50% by 10
years,250,257,258,261-263 but may occur even 13 years after diag-
nosis.258 Anterior laminectomy, vertebroplasty and
kyphoplasty are useful in patients with vertebral insta-
bility or bone particles compressing the cord.221,261
Patients with an unsuspected marrow lesion,264 and/or
persistence of MC after radiotherapy263 are at a greater
risk of progression. However, most patients whose plas-
macytoma transforms to MM probably had a systemic
multifocal disease not revealed by standard X-ray imag-
ing but possibly identifiable by MRI and PET.265,266 A ran-
domized trial267 and other controlled studies268,254 showed
a certain survival benefit from prophylactic chemother-
apy, however, other studies did not.257,269,270
SEP accounts for 3-4% of all plasma cell disorders
and is often localized in the upper aerodigestive tract.
The prognosis of patients with SEP appears to be bet-
ter than that of patients with SBP because approxi-
mately 70% of patients with SEP remain disease-free at
10 years.271 Radiation therapy to the target area and
adjacent lymph nodes can achieve local control in more
than 80% of the cases, especially if they are small size
tumors with a low-to-intermediate histologic grad-
ing.253,254 Relapse in regional lymph nodes is frequent only
in those patients not receiving radiation to the
nodes.254,272 Surgery can also achieve very good results in
the case of SEP of the aerodigestive tract, especially if
the resection potential is good.255 Combined radiation
and surgery have better results when complete surgical
tumor resection is doubtful or impossible and/or if
lymph node areas are affected.254 Local recurrence
occurs in approximately 20% of SEP, while progression
to MM occurs in less than 20% of the patients.255,264,273
Overall the 5-year OS is 40% for pulmonary location274
and 60-82% for head-and-neck locations.275,276 Only one
level 2- study verified the impact of prophylactic
chemotherapy in this setting and found no advantage
on either relapse rate or PFS.268 More recently, Dimopou-
los et al.271 also concluded that there is no role for sys-
temic chemotherapy in the management  of SEP or SBP.
Recommendations
Local radiotherapy is the treatment of choice for new-
ly diagnosed solitary bone plasmacytoma and primary
extramedullary plasmacytoma: 45-50 Gy should be pro-
vided to the involved field, including a margin of normal
tissue (grade C).
Surgery is recommended for patients with solitary
bone plasmacytoma with vertebral instability or for fix-
ation of a long bone (grade D) and for patients with
extramedullary plasmacytoma of the upper aerodiges-
tive tract which has a good resection potential (grade
D). Prophylactic chemotherapy is not recommended
(grade B). After radiotherapy, patients should have twice
yearly monitoring of serum and urine electrophoresis
and immunofixation, serum calcium and creatinine and
full blood count (grade D). Skeletal X-rays should be per-
formed at least once a year and when patients are symp-
toms (grade D).
Discussion
The present guidelines are based on the most updat-
ed and comprehensive review of literature on MM ther-
apy. This literature provided the basis for evidence to be
translated into therapy recommendations. The consen-
sus methodology was employed with caution and con-
sensus-based statements are explicitly marked with a D
grade. Indeed, the Expert Panel deemed it appropriate to
fill some evidence gaps, providing recommendations
based on indirect evidence and personal experience,
after a methodologically constrained discussion.
Comparisons with currently available guidelines are
shown in Table 2 and Table 3.277-286 All the published
guidelines agree on the criteria to start therapy and on
the usefulness of autologous SCT as a frontline therapy,
however, the cutoff age to undergo autologous SCT var-
ied. The guidelines also concurred on two major aspects
of autologous SCT: the source of stem cells (peripheral
blood unpurged stem cells) and the use of high-dose
melphalan without TBI. Regarding first-line standard
chemotherapy, all the guidelines agreed that oral mel-
phalan was a well consolidated and effective strategy,
however, some guidelines recommended the association
with prednisone or prednisolone (Table 2). Most of the
guidelines indicated alternative options to melphalan,
such as MP-based combination chemotherapy,
haematologica 2004; 89(6):June 2004730
G. Barosi et al.
 
cyclophosphamide or high-dose dexamathasone plus
thalidomide. IFN-α was not accepted as a standard
maintenance therapy after conventional chemotherapy
by any of the guidelines due to its low clinical benefit,
negative impact on quality of life and high cost. Front-
line allogeneic SCT for the younger patients was usual-
ly considered as an experimental option, due to the high
TRM. Non-myeloablative SCT was considered a valuable
experimental option, too, since the guidelines deemed
that it was worth further studies before being imple-
mented in clinical practice.
A few guidelines systematically addressed second-line
therapies but only the present one provides extensive
recommendations on thalidomide use in relapsed and/or
refractory patients. Finally, the present guidelines are
the only ones to address therapies for all the relevant
complications of MM: in particular they are the only
guidelines providing recommendations on the manage-
ment of MM-related amyloidosis.
Despite the evidence-based nature of most of the rec-
ommendations, there are intrinsic limitations in the
process of translating evidence into practice recom-
mendations.287 In particular, the trade-offs between tox-
icity and uncertain benefit (e.g. allogeneic SCT) or
between quality of life and survival prolongation are
subjective in nature and may be changed by incoming
studies. Secondly, equivalence between therapies is
sometimes implicitly assumed (i.e. between different bis-
phosphonates for bone lesions) despite no trial being
adequately powered and designed to test an equiva-
lence hypothesis or there being no head-to-head trial.
Finally, some recommendations are based on indirect
evidence, intermediate outcomes or experts’ opinion and
may therefore be inconsistent with future pieces of evi-
dence. These uncertainties are explicity declared in the
recommendations, whose grading score is mainly relat-
ed to these uncertainties. Moreover, the present guide-
lines do not stress financial or psychological issues of
MM therapy. Indeed, some expensive therapies, such as
autologous SCT,288,289 have been reported to be cost-effec-
tive,290,291 while others, such as IFN-α, are not.292,293
More than 60 relevant papers have already been pub-
lished since the last meeting of the Expert Panel. There-
fore, the present guidelines are intended to be valid for
the next 2 years, after which they will require a revision.
Addendum: Literature review up to 31
December 2003
Since the present guide-lines were based on a sys-
tematic review of literature published up to 31st May,
2003, a further analysis of data published since that date
up to 31st December 2003 was performed before publi-
cation of the paper. We found 5 randomized controlled
studies dealing with therapy of MM published in full and
we selected 3 randomized trials presented in abstract
form during the 2003 ASH Meeting.
To investigate whether combination chemotherapy
with vincristine, cyclophosphamide, prednisolone, and
melphalan (COP/ MP) with the addition of ranimustine
(MCNU) (MCNU-COP/MP) is superior to the slightly
modified COP/MP (mCOP/MP) regimen in MM, in a mul-
ticenter randomized study 210 patients with newly diag-
nosed, overt MM not treated with chemotherapy were
randomized to receive either MCNU-COP/MP or
mCOP/MP.294 The response rate to mCOP/MP was 43.7%
and that to MCNU-COP/MP was 56.1% (p = 0.097). The
progression-free survival (PFS) was significantly longer
for patients treated with MCNU-COP/MP than for
patients treated with mCOP/MP (median, 23.0 months
versus 15.8 months, p = 0.014). No significant differ-
ence in overall survival rate was observed between the
groups (median, 49.9 months versus 44.0 months, p =
0.75). In conclusion, the study documented that addition
of MCNU to mCOP/MP has no benefit on survival.
Ninety patients with untreated, stage I-II A myeloma,
were randomized to receive or not monthly infusions of
pamidronate for 1 year, without additional therapies.295
Three years after the start of the treatment, the disease
had progressed in 25% of pamidronate-treated patients
and in 26.8% of controls (p = n.s). Among the 21
patients who required chemo-radiotherapy, skeletal
events developed in 9/11 (81.8%) controls and in 4/10
(40%) of treated patients (p < 0.01). Patients with
advanced breast carcinoma or MM (n = 1648) were ran-
domized to receive 4 mg or 8 mg (reduced to 4 mg) zole-
dronic acid as a 15-minute infusion or to receive 90 mg
pamidronate as a 2-hour infusion every 3-4 weeks for
24 months.296 In patients with MM, after 25 months of
follow-up, zoledronic acid reduced the overall proportion
of patients with a skeletal event and reduced the skele-
tal morbidity rate to a similar degree as pamidronate.
A prospective randomized study was designed to
compare the  objective response rates of two VAD-like
outpatient regimens as primary treatment for sympto-
matic patients with MM.297 One hundred and twenty-
seven patients received a VAD bolus, which consisted of
vincristine 0.4 mg i.v., doxorubicin 9 mg/m2 i.v. and dex-
amethasone 40 mg p.o. daily for four consecutive days
and 132 patients received VAD doxil, which consisted of
vincristine 2 mg i.v. and liposomal doxorubicin 40 mg/m2
i.v. on day 1 and dexamethasone 40 mg p.o. daily for 4
days. The two regimens were administered every 28
days for four courses and in courses 1 and 3, in both
arms, dexamethasone was also given on days 9-12 and
17-20. An objective response was documented in 61.4%
and 61.3% of patients treated with VAD bolus and VAD
doxil, respectively. The results indicated that both VAD
bolus and VAD doxil can be administered to outpatients
and can provide an equal opportunity of rapid response
in many patients with MM.
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Table 2. Comparison of currently available guidelines for front-line multiple myeloma treatment.
UK-MF277 CCO-PGI278 FMSD279 BCCA280 NCCN281 ASBBMT282 IMF283 Present 
guideline
Date of Oct 2002 Oct 2002 Dec 2001 May 2000 2001 Jan 2003 May 2003
publication
Evidence June 2001 April 2000 n.a. n.a. June 2002 n.a. March 2003
collection
Grading of yes yes yes yes yes no yes
evidence
Candidates for watch and wait
Asymptomatic pts^ All n.a. All Selected^^ All All All Selected^^^
Front-line standard dose chemotherapy
Not candidates Mel, MP; Mp or MP or Mp Mp° Mp, VPMCP, n.a. MP; VAD, Mp°
for ASCT Ctx; ABCM° combination VAD, VBAP thalidomide + HD-Dex,
Cht Cytoxan, VAD-based
Candidates VAD-like VAD-like n.a. Not Mp Not alkylating n.a. VAD, VAD×4
for ASCT agents or thalidomide + HD-Dex, 
nitrosureas Cytoxan
Renal failure VAD, HD-Dex − n.a. n.a. HD-Dex and
VAD-based
chemotherapy
Maintenance Effective but − n.a. Not Equivalent to n.a. In clinical trials Possible
with IFN-α not cost-effective recommended steriods or (steroids are option
no maintenance an option) +/- steroids
Front-line autologous stem cell transplantation 
Candidates cut-off 60/70 yrs§ <55/60 yrs <65-70 yrs n.a.§ Preferred as <70 yrs <65/70 yrs 
age early therapy 
Excluded if renal failure No Yes − − − No No
Other exclusion criteria Low performance Severe 
status comorbidity
Source of stem cells − Peripheral − − Peripheral Peripheral Peripheral
Purging of stem cells No In clinical trials − − No No No
Selection of stem cells − Insufficient data − − Insufficient data − No
Preparative regimen Mel Mel200 +/- TBI§§ Melphalan Mel200 Mel200
200 (no TBI)
Maintenance IFN-α Effective No In clinical Insufficient In clinical In clinical
but not consensus trials data trials trials
cost-effective
Tandem transplantation In clinical No Insufficient In clinical Recommended
trials standard use data trials
Allogeneic stem cell transplantation
Front-line To be Inferior In clinical Less preferred To be considered In clinical
allogeneic SCT considered* to autologous trials# than autologous in the younger trials###
(from sibling donor) SCT at present: SCT patients##
not recommended routine
Syngeneic SCT n.a. n.a. n.a. Recommended Recommended 
up to 65 years
Non-myeloablative In clinical n.a. n.a. In clinical In clinical In clinical
allogeneic SCT trials trials trials trials
DLI Persistent or n.a. Feasible n.a. Relapsed
progressive disease option or progressed
disease
UK-MF: United Kingdom Myeloma Forum; CCO-PGI: Cancer Care Ontario Practice Guideline Initiative; FMSD: Finnish Medical Society Duodecim; NCCN. National Cancer Care
Network; IMF: International Myeloma Foundation; BCCA: British Columbia Cancer Agency; MP: oral melphalan + prednisolone; Mp: oral melphalan + prednisone; Mel200: mel-
phalan 200 mg/m2; Mel140TBI : melphalan 140 mg/m2 plus total body irradiation; ^ no related organ damage nor symptoms; ^^asymptomatic and without urinary; Bj: <2 bone
lesions; stable MC: ^^^ without chromosome 13 deletion. §Preferred option for some patients not progressing during first-line chemotherapy and with sufficient renal, cardiac or liver
function; §§TBI-free preparative regimens should be used for those patients who have received previous radiotherapy* Up to 50 years of age # Younger patients with responsive or stable
disease after primary chemotherapy; ###Patients with chromosome 13 deletion and age <50 years ## with a CMV negative HLA-matched donor ° until plateau.
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The efficacy of intensified chemotherapy followed by
myeloablative therapy and autologous stem cell rescue
was compared with that of intensified chemotherapy
alone in 261 patients younger than 66 years newly diag-
nosed with stage II/III disease MM.298 Patients were ran-
domized after remission induction therapy with VAD to
receive intermediate-dose melphalan (IDM) without
stem cell rescue (n = 129) or the same regimen fol-
lowed by myeloablative therapy consisting of
cyclophosphamide, total body irradiation, and autolo-
gous stem cell reinfusion (n = 132). Interferon-α-2a
was given as maintenance treatment. Of the eligible
patients, 79% received both cycles of IDM and 79% of
allocated patients actually received myeloablative
treatment. The response rate (complete remission plus
partial remission) was 88% in the intensified
chemotherapy group versus 95% in the myeloablative
treatment group. Complete remission was significantly
higher after myeloablative therapy (13% versus 29%; p
= 0.002). With a median follow-up of 33 months (range,
8-65 months), the event-free survival was not different
between the two treatment groups (median 21 months
versus 22 months; p = 0.28). Time to progression was
significantly longer after myeloablative treatment (25
months versus 31 months; p = 0.04). The overall survival
was not different (50 months versus 47 months; p =
0.41). The conclusion of the trial was that intensified
chemotherapy followed by myeloablative therapy as
first-line treatment for MM resulted in a higher CR and
a longer time to progression than did intensified
chemotherapy alone, without a better EFS and OS. 
The ECOG, CALGB and SWOG enrolled 899 patients
with newly diagnosed MM to receive VAD induction ×
4 cycles (n=805), followed by randomization to a single
PBSC-supported HDT (n=258) vs VBMCP (n=252).299
Responders to VBMCP or HDT were randomized to
receive or not IFN. Response rates were similar with
HDT/VBMCP. Progression-free survival was superior after
HDT (25 vs 21 months, p = 0.05).
With the aim of comparing HDT/SCT versus continued
conventional chemotherapy in MM patients responding
to the initial treatment (4 courses of alternating BVM-
CP/VBAD), 216 patients were randomized to receive 8
additional courses of  BVMCP/VBAD or intensification
with HDT/HSC, melphalan 140mg/m2/TBI or melphalan
200 mg/m2.300 Complete response, i.e. negative elec-
trophoresis, was significantly higher in the HDT/SCT arm
(30% vs 11%). However, PFS was not significantly dif-
ferent between recipients of HDT/SCT and conventional
chemotherapy. Preliminary results of the two protocols
(IFM9903 and IFM 9904) comparing autologous fol-
lowed by miniallogeneic transplantation and double
Table 3. Comparison of currently available guidelines for supportive multiple myeloma therapy.
UKMF277 BCCA280 NCCN281 IMF283 ASCO/ASH284,285 Present
guidelines
Date of publication October 2002 May 2000 2001 May 2003 October 2002
Evidence collection June 2001 n.a. n.a. January 2002 (bisph) March 2003
Dec 2000 (epoetin)
Intravenous Possible To be considered May be a n.a. Severe recurrent
immunoglobulins utility if recurrent helpful infections hypogamma
life-threatening adjuntive and globulinemia§
infections polyclonal measure 
in management of 
infections 
Plasma Recommended May be considered n.a. n.a. Recommended for
exchange for hyperviscosity for hyperviscosity hyperviscosity
syndrome syndrome syndrome
Bisphosphonates Clodronate or Pamidronate In all patients To treat Long-term Long-term
pamidronate until active with bone lesions hypercalcemia pamidronate clodronate,
recommended for treatment or osteopenia or zoledronic pamidronate
all MM pts of MM is and/or acid in patients or zoledronic
Intervanous  abandoned# hypercalcemia with bone lesions acid to
bisphosphonates or ostheopenia patients with 
for hypercalcemia bone lesions or 
severe osteopenia
Erythropoietin Symptomatic Persistent Persistent Hb<10 g/dL
anemia or symptomatic anemia
chronic renal failure anemia (Hb<10g/dL)  despite 
chemotherapy
§or undergoing allogeneic SCT from unrelated donor and presenting severe hypogammaglobulinemia within the first 1000 days post-transplant; #reduce dosage after two
years. 
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autologous transplant in high-risk de novo MM patients
showed that both strategies lead to survival rates supe-
rior to 50% at 3 years on an intent-to-treat basis.301 The
strength of evidence was in no case sufficient to ques-
tion the validity of the recommendations of these
guidelines.  
After submission of the paper, author-based recom-
mendations for the treatment of MM and guidelines on
the diagnosis and management of solitary plamacy-
toma of bone and solitary extramedullary plasmacy-
toma have been issued.302-303
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and design of these guidelines and to the analysis and interpretation
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approval of the version to be published. GB and MM were responsi-
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